5 Best Long Term Stocks To Own For 2014

The following video is from Tuesday's MarketFoolery podcast, in which host Chris Hill and analysts Jason Moser and Andy Cross discuss the top business and investing stories of the day.

Shares of Buffalo Wild Wings (NASDAQ: BWLD  ) slipped today after the restaurant chain reported an 11% decline in first-quarter earnings. Same-store sales fell 1.4% for company-owned locations compared to a 2.2% decline in franchised locations. Does the disparity suggest bigger problems ahead? Does Buffalo Wild Wings still have room to grow? In this installment of MarketFoolery, our analysts discuss the future of Buffalo Wings.

The best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of.�Click here now�to keep reading.

Top Penny Companies To Watch For 2015: Rudolph Technologies Inc.(RTEC)

Rudolph Technologies, Inc. designs, develops, manufactures, and sells process control defect inspection, metrology, and process control software systems to microelectronics device manufacturers. The company provides yield management solutions for use in wafer processing and final manufacturing through a range of standalone systems for macro-defect inspection, test systems, and transparent and opaque thin film measurements. It also offers a range of process control software solutions for semiconductor, solar, and LED manufacturing. It provides products for various applications in the areas of macro-defect detection and classification, diffusion, etch, lithography, CVD, PVD, and CMP. The company sells its products and solutions to logic, memory, data storage, and application-specific integrated circuit device manufacturers. It sells its products in the United States, Taiwan, China, Singapore, South Korea, Japan, and Europe. The company was founded in 1940 and is based in Fla nders, New Jersey.

Advisors' Opinion:

• [By John Emerson]

  Orbotech (ORBK) and Rudolph Technologies (RTEC) Sizable Net-Nets in the AOI Sector

  As noted previously, I rode the elevator up and then back down on Camtek (CAMT), a tiny Israeli automated optical inspection (AOI) company. By late 2008 the company had fallen to below $1 per share. Both of Camtek�� larger rivals, RTEC and ORBK, had dropped to absurdly low levels by November 2008. I used the opportunity to switch out of CAMT and some of my other losing propositions in favor of these superior companies. In the process, I created a large amount of tax loss carry-forwards which would allow me to minimize my future taxation when I decided to sell these cyclical entities.

• [By John Emerson]

  In case you are wondering, I only made peanuts on what should have been a monumental success. You see I never sold a share of Camtek until the autumn of 2008. I exchanged them for shares in their arch rivals Orbitech (OBRK) and Rudolph (RTEC) which had become large net/net propositions (more on those purchases of ORBK and RTEC later in the series).

• [By Seth Jayson]

  Basic guidelines
  In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at Rudolph Technologies (Nasdaq: RTEC  ) out of line? To figure that out, start by comparing the company's inventory growth to sales growth. How is Rudolph Technologies doing by this quick checkup? At first glance, not so great. Trailing-12-month revenue increased 17.6%, and inventory increased 32.2%. Comparing the latest quarter to the prior-year quarter, the story looks potentially problematic. Revenue dropped 8.9%, and inventory grew 32.2%. Over the sequential quarterly period, the trend looks worrisome. Revenue dropped 23.3%, and inventory grew 10.8%.

• [By Ben Axler]

  In the table below, we've listed a sample of small-cap semiconductor capital equipment stocks such as Entegris (ENTG), Advanced Energy Industries (AEIS), ATMI Inc. (ATMI), MKS Instruments (MKSI), Photronics Inc. (PLAB), Rudolph Technologies (RTEC),FormFactor (FORM) and Mattson Technology (MTSN). The peers trade at approximately 1.0x and 15.5x 2014E revenues and EPS, respectively. Furthermore, the average peer trades at 2.1x tangible book value. However, these multiples are based on average 2014E industry revenue and earnings growth of 18% and 119%, respectively. Axcelis is poised to grow at a rate substantially above the industry average.

5 Best Long Term Stocks To Own For 2014: Xylem Inc (XYL)

Xylem Inc. (Xylem), formerly ITT WCO, Inc., incorporated on May 4, 2011, is a provider of equipment and service for water and wastewater applications with a portfolio of products and services addressing the full cycle of water, from collection, distribution and use to the return of water to the environment. It operates in two segments: Water Infrastructure and Applied Water. The Water Infrastructure segment focuses on the transportation, treatment and testing of water, offering a range of products, including water and wastewater pumps, treatment and testing equipment, and controls and systems. Key brands in this segment include Flygt, Wedeco, Godwin Pumps, WTW, Sanitaire, AADI and Leopold. The Applied Water segment encompasses the uses of water and focuses on the residential, commercial, industrial and agricultural markets. The segment�� products include pumps, valves, heat exchangers, controls and dispensing equipment. Key brands in this segment include Goulds Water Technology (Goulds), Bell & Gossett, AC Fire, Standard, Flojet, Lowara, Jabsco and Flowtronex. The Company sells its products in more than 150 countries through a distribution network consisting of its direct sales force and independent channel partners. On October 31, 2011, ITT Corporation completed Spin-off of Xylem, formerly ITT�� water equipment and services businesses. The Spin-off was completed pursuant to the Distribution Agreement, dated as of October 25, 2011, among ITT, Exelis Inc. (Exelis) and Xylem. In July 2012, it acquired MJK Automation A/S. In March 2013, it acquired MultiTrode Pty Ltd.

Water Infrastructure

Water Infrastructure involves the process that collects water from a source and distributes it to users, and then returns the wastewater to the environment. Water Infrastructure serves three applications: transport, treatment and test of water and wastewater for two types of customers: public utilities and industrial facilities. The Transport application includes all of the equipment and s! ervices involved in the movement of water from sources, such as oceans, lakes, rivers and ground water, to treatment facilities, and then to users. It also includes the movement of wastewater from the point of use to a treatment facility and then back into the environment. The Company serves the equipment markets, such as water and wastewater submersible pumps, monitoring controls, and application solutions. With operations on six continents, it also has dewatering rental fleet, serviced with the Company�� Flygt and Godwin brands. In its Water Infrastructure Segment, Transport accounted for approximately 73% of its consolidated revenue during the year ended December 31, 2011. Flygt is the manufacturer of submersible pumps, mixers, and aeration equipment for use in environments, such as water and wastewater treatment, raw water supply, abrasive or contaminated industrial processes, mining and crop irrigation. Flygt products have applications in various markets, including wastewater lift stations, water and wastewater treatment facilities, pressurized sewage systems, oil and gas, steel, mining and leisure markets. Customers include public utility wastewater and clean water treatment facilities, oil and gas platforms, and steel manufacturing companies.

Godwin Pumps is engaged in pump manufacturing. It manufactures, sells, rents and services products that are customized to the specific needs of its clients. Godwin Pumps��products include the fully automatic self-priming Dri-Prime pump, a range of Sub-Prime electric and Heidra hydraulic submersible pumps, Wet-Prime gasoline-powered contractor pumps and a line of generators and portable light towers. Godwin products are primarily used in construction, disaster recovery, flooding, heavy industry, marine use, mining, oil, gas and chemical extraction, refineries, temporary fire protection and water and wastewater transport. Customers include industrial plants, construction contractors, public utility wastewaters and clean water treatment and tr! ansportat! ion facilities, oil, gas and chemical drilling outfits, and refineries. Godwin�� fleet of equipment is rented through 33 United States branches and a global network of distributors. The Treatment application includes equipment and services that treat both water for consumption and wastewater to be returned to the environment. Leopold is the Company�� filtration brand. Disinfection systems, both ultraviolet (UV) and ozone oxidation, treat both public utility drinking water and wastewater, as well as industrial process water, and are provided through its WEDECO brand. Biological treatment systems are key to the treatment of solids in wastewater plants, which is provided through its Sanitaire brand. In its Water Infrastructure Segment, Treatment accounted for approximately 18% of its consolidated net sales in 2011.

The Company�� Sanitaire brand provides biological wastewater treatment solutions for public utility and industrial applications. Sanitaire�� offering includes diffused aeration, sequencing batch reactors, drum filters and state-of-the-art controls. Sanitaire is a brand in diffused aeration, which is a process that introduces air into a liquid, providing an aerobic environment for degradation of organic matter. Principal Sanitaire customers are public utility and industrial wastewater treatment facilities. WEDECO develops chemical-free and environmentally friendly water treatment technologies, including ultraviolet light and ozone systems. There are over 250,000 installed WEDECO systems for UV disinfection and ozone oxidation globally in private, public utility and industrial locations. Customers include public utility wastewater and clean water treatment facilities, power plants, pulp and paper mills, food products manufacturers and aquaculture facilities. Leopold is a gravity media filtration and clarification solutions for the water and wastewater industry. Nova Analytics, its served market is focused on water and the environment for quality levels throughout the water in! frastruct! ure loop.. Analytical systems are applied in three primary ways: in the field, in a facility laboratory, or real time, online monitoring in a treatment facility process. In its Water Infrastructure Segment, Test accounted for approximately 9% of its consolidated net sales in 2011.

In wastewater treatment facilities, WTW-branded systems monitor parameters, such as dissolved oxygen, pH, and turbidity throughout the water process. WTW�� product offering includes meters, sensors, data-loggers, photometers and software. Aanderaa Data Instruments AS (AADI) offers sensors, instruments and systems for measuring and monitoring in environments, such as rivers, oceans and the polar regions through networked systems using wireless technology that monitors temperature, salinity, oxygen, turbidity, current and waves for ecosystem health. The main market areas are marine transportation, environmental and ocean research, oil and gas, aquaculture, road and traffic, and construction. Oceanography International Corporation (OI Analytical) provides products used for chemical analysis. The Company develops, manufactures, sells, and services analytical instruments that detect, measure, analyze, and monitor chemicals in liquids, solids, and gases. Yellow Springs Instrument Company (YSI) develops and manufactures sensors, instruments, software and data collection platforms for environmental and coastal water quality monitoring and testing. YSI also offers life sciences products, including biochemical analyzers for bioprocess monitoring, food and beverage processing, and sports physiology. The main market areas are marine transportation, environmental and ocean research, oil and gas, aquaculture, road and traffic, and construction.

Applied Water

Applied Water encompasses all the uses of water. Its served market consists of the main uses of global water: Building Services, Industrial Water and Irrigation. The Building Services is defined by four main uses of water in building services ! applicatio! ns, such as in residential homes and commercial buildings, including offices, hotels, restaurants and malls. The first is the supply of potable water for consumption, such as for drinking and hygiene. The Goulds brand offers pumps and boosting systems utilized within buildings, sourcing water from distribution networks or from wells. The second application is wastewater removal with sump and sewage pumps. The third application is in heating, ventilation and air conditioning (HVAC), where Bell & Gossett specializes in pumps and valves that are used in water-based heating and cooling systems. The fourth water-related building service area is fire protection, where its AC Fire brand supplies full pump systems for emergency fire suppression. In Europe, Lowara is a brand in the commercial and residential water market with applications in the four main uses of water. In its Applied Water Segment, Building Services accounted for approximately 51% of its consolidated net sales in 2011.

The Company�� Goulds brand supplies vertical multistage pumps to boost pressure for purposes , such as circulating water through a manufacturing facility to cool machine tools. Its Lowara brand focuses on water treatment, industrial washing equipment and machine tool cooling. The Standard brand delivers heat exchangers for combined heat and power (CHP) applications within power generation plants. It also provides applications, such as flexible impeller pumps for wine processing facilities served by its Jabsco brand, and water-based detergent dispensing and water circulation within car washes served by Flojet and Goulds air-operated diaphragm and end suction pumps. In its Applied Water Segment, Industrial Water accounted for approximately 42% of its consolidated net sales in 2011. The irrigation business consists of irrigation-related equipment and services associated with bringing water from a source to the plant or livestock need, including hoses, sprinklers, center pivot and drip irrigation. The Company focuses ! on the pu! mps and boosting systems that supply this ancillary equipment with water. Its Goulds brand brings mixed flow pumps, and its Flowtronex group specializes in equipment solutions, such as the Hydrovar boosting system, which incorporates monitoring and controls. Its Lowara brand also produces pumps for agriculture applications and irrigation of gardens and parks. In its Applied Water Segment, Irrigation accounted for approximately 7% of the Company�� consolidated net sales in 2011.

Advisors' Opinion:

• [By Ben Levisohn]

  Stocks received a respite from the selling today as Michael Kors�(KORS), Yum Brands (YUM),�Merck�(MRK),�Pfizer�(PFE) and�Xylem�(XYL) gained.

• [By Jim Jubak]

  I wouldn't exactly call it super enthusiastic guidance, but this quarter, when so few companies have anything good to say about their business for the fourth quarter, even Xylem's (XYL) tepid enthusiasm stands out.

5 Best Long Term Stocks To Own For 2014: Pharmacyclics Inc (PCYC)

Pharmacyclics, Inc., incorporated on April 19, 1991, is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�� tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.

As of June 30, 2012, the Company developed ibrutinib, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a variety of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse B-cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its current or planned Phase Ib/II and Phase III development program. had development programs for B-cell malignancies and autoimmune diseases. For malignant indications it has developed PCI-32765, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its Phase II development. It has developed an assay! to measure occupancy of Btk in PBMCs using a cell-permeable fluorescently-labeled derivative of PCI-32765.

Factor VII is an enzyme that becomes activated (FVIIa) by binding to the cell surface protein tissue factor (TF), a protein found in the body that helps to trigger the process of blood clotting in response to injury. TF is over expressed in many cancers including gastric, breast, colon, lung, prostate, ovarian and pancreatic cancers. In these tumors, the FVIIa/TF complex induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2), another cell-surface protein. This in turn increases the expression of interleukin-8 (IL-8), a protein produced by white blood cells and other immune cells in response to pathogenic stimulation, and vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate the growth of blood vessels. Both proteins play an important role in tumor growth and metastases as well as angiogenesis (growth of new blood vessels). FVIIa/TF complex also initiates the coagulation (a process by which blood forms clots) processes implicated in the high incidence of thromboembolic (the process by which the blood clots within a blood vessel) complications seen in patients with TF-expressing cancers. Thromboembolic events are a cause of death in patients with cancer and anticoagulant treatment has been shown to improve survival in a variety of cancers (Klerk et al. JCO. 2005).

PCI-27483 Factor VIIa Inhibitor

The Company�� Factor VIIa inhibitor PCI-27483 is a first-in-human small molecule inhibitor that selectively targets FVIIa. As an inhibitor of FVIIa, PCI-27483 has two potential mechanisms of action: inhibition of intracellular signaling involved in tumor growth and metastases and inhibition of early coagulation processes associated with thromboembolism.

Factor VIIa PCI-27483 Clinical Development Update

A multicenter Phase I/II of PCI-27483 in patients with locally a! dvanced o! r metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). The objectives are to assess the safety of FVIIa Inhibitor PCI-27483 at pharmacologically active dose levels, to assess potential inhibition of tumor progression and to obtain initial information of the effects on the incidence of thromboembolic events. Due to a paradigm shift away from the use of gemcitabine alone for the treatment of pancreatic cancer, enrolling patients in this randomized study has been challenging. PCYC is evaluating other alternatives for development of this agent.

A multicenter Phase I/II of PCI-27483 in patients with locally advanced or metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). PCI-27483 is covered by United States patents and patent applications and counterpart patents and patent applications in fourteen ex-United States territories, including Europe, Canada, Mexico, Japan, China, India, South Korea, Australia and Brazil.

Advisors' Opinion:

• [By John McCamant]

  The company��hich we consider conservative among biotech stocks��s Pharmacyclics (PCYC). Its pill is also expected to be approved for a much larger B-cell cancer market, chronic lymphocytic leukemia (CLL), by the end of February.

• [By Keith Speights]

  Pharmacyclics (NASDAQ: PCYC  ) and development partner Janssen, a division of Johnson & Johnson (NYSE: JNJ  ) , announced on Wednesday that a New Drug Application, or NDA, has been submitted for ibrutinib. The NDA filed with the U.S. Food and Drug Administration requests marketing approval for the drug in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma and in the treatment of previously treated patients with mantle cell lymphoma.

• [By Sean Williams]

  We've witnessed first-hand what a crapshoot the space can be. Four years ago,�Pharmacyclics (NASDAQ: PCYC  ) looked like just another biotechnology company that was going to waste away into nothing with its share price trading for less than $1. In the years since, it's forged nearly a $1 billion licensing partnership with Johnson & Johnson (NYSE: JNJ  ) for its relapsed/refractory mantle cell lymphoma and chronic lymphocytic leukemia drug hopeful, Ibrutinib, and delivered some of the strongest overall response rates ever witnessed in trials for these two diseases. Shares of Pharmacyclics closed yesterday above $80 per share.

• [By John Udovich]

  Bubble talk, biotech IPO setbacks plus news�about small cap biotechs like Intrexon Corp (NYSE: XON) and TNI BioTech (OTCMKTS: TNIB) have dominated biotech news this week or in recent weeks. Just consider the following news:

  Why There is No Biotech Bubble & Where to Look for Value in Biotech. Marshall Gordon, the Director and senior health-care analyst of ClearBridge Investments, was recently interviewed by Barron�� where he stated his belief that there is no biotech bubble because biotech stocks have delivered new drugs and have shown an ability to innovate. With that said, he added that the sector got ahead of itself while some biotechs suffered setbacks plus hedge funds decided to trim risk from their portfolios. Nevertheless, Marshall likes or is watching mid cap biotechs BioMarin Pharmaceutical Inc (NASDAQ: BMRN) and Pharmacyclics, Inc (NASDAQ: PCYC) along with small cap biotechs�Pacira Pharmaceuticals Inc (NASDAQ: PCRX) and Clovis Oncology Inc (NASDAQ: CLVS). He also added that recent biotech IPOs have been lesser quality names than earlier offerings. A Trio of Biotech�IPO Setbacks. FierceBiotech has�summarized how a trio of biotech IPO have suffered setbacks. Specifically, Relypsa (NASDAQ: RLYP), a late-stage biotech developing a treatment for hyperkalemia,�slashed its asking price on 6.9 million shares to $12 a share to raise $82 million�from a range of $16 to $19 a share while�Xencor (NASDAQ: XNCR), a biotech developing antibodies for severe autoimmune/allergic diseases and cancer,�has dropped its IPO price to $7 a share to raise $75 million from a range of $14 to $16. Meanwhile, Celladon, which is developing a first-in-class gene therapy for patients with systolic heart failure, has postponed its IPO citing poor market conditions. Coming�Biotech IPOs. Nevertheless, FierceBiotech has noted that GeNO Healthcare (NASDAQ: GNO) is looking to raise $50 million for its�new, patient-friendly approach for delivering inhaled nitric oxide on the

5 Best Long Term Stocks To Own For 2014: Cincinnati Bell Inc (CBB)

Cincinnati Bell Inc., together with its subsidiaries, provides telecommunications and technology services. The company?s Wireline segment provides local voice services, including local telephone service, switched access, and value-added services, such as caller identification, voicemail, call waiting, and call return; data services comprising high-speed Internet using digital subscriber line technology, fiber to the home, dial-up Internet access, network access, and gigabit Ethernet and asynchronous transfer mode data transport services. This segment?s services also comprise long distance and voice over Internet protocol (VoIP)services, such as long distance voice, audio conferencing, VoIP, and other broadband services; entertainment services that consist of television over fiber optic cable and coaxial cable in limited areas, and DirecTV commissioning over the company?s operating area; and other services consisting of security monitoring, inside wire installation for busi ness enterprises, rental revenue of space, public payphones, and clearinghouse services. It?s Wireless segment provides advanced digital wireless voice and data communications services through the wireless network in a licensed service territory, which includes Greater Cincinnati and Dayton, Ohio, and areas of northern Kentucky and southeastern Indiana. This segment offers postpaid and prepaid wireless subscription services; and wireless handset devices to customers to use its wireless services. The company?s Data Center Colocation segment provides data center colocation services to businesses. This segment operates 17 data centers with 639,000 square feet of total data center space in Texas, Ohio, Kentucky, Indiana, Michigan, and Illinois. It?s IT Services and Hardware segment offers a range of managed IT solutions, including managed infrastructure services, IT and telephony equipment sales, and professional IT staffing services. The company was founded in 1873 and is based in Cincinnati, Ohio.

Advisors' Opinion:

• [By Paulo Santos]

  The birth of CONE was non-effusive; it came from the spin-off and IPO of the datacenter unit of Cincinnati Bell (CBB). Perhaps one could believe that not being a green field company, people didn't go as gaga on it. It came from a telecom dinosaur, after all.

• [By Jim Royal]

  One of my favorite reasons to reinvest in stocks I already own is when an uncertain, but favorable catalyst occurs, but the stock does little. So my Special Situations portfolio is adding $1,000 to each of the following three stocks: Cincinnati Bell (NYSE: CBB  ) , Bridgepoint Education (NYSE: BPI  ) , and First Financial Northwest (NASDAQ: FFNW  ) . Read on to see why.

• [By Mike Arnold]

  Cincinnati Bell (CBB) ("CB" or "the company") is a storied, regional telecommunications player in Ohio undergoing considerable transformation, which began, in earnest, with the spin-off of its data warehousing business CyrusOne (CONE) ("Cyrus") in January 2013. CB still holds a ~69% economic interest in Cyrus, with the stated goal to monetize the asset over the next several years in order to pay down debt.